Cipla gets nod for generic version of Shire’s Firazyr

Pharma major Cipla has announced that the company has received the final approval for its Abbreviated New Drug Application (ANDA) for Icatibant Injectable 30mg/3mL from the United States Food and Drug Administration (US FDA).

Cipla’s Icatibant Injectable Pre-Filled Syringe 30mg/3mL is AP-rated generic version of Shire’s Firazyr.The purpose of the Icatibant injection is for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.

  • Related Posts

    US FDA and Telangana DCA bolster global pharma safety at second regulatory forum

    Hyderabad: The collaborative landscape of international pharmaceutical oversight reached a new milestone on May 5, 2026, as the Drugs Control Administration (DCA) of Telangana hosted the Second Regulatory Forum with…

    Nishant as Health Minister, Bihar is all set to witness a New Dawn of Healthcare

    Spiritualism n Compassion being core of his Nature, Poor Patients may Hope for Best New Delhi: ‘Nishant’ literally meaning daybreak, Bihar may well hope to see a new Dawn of…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    US FDA and Telangana DCA bolster global pharma safety at second regulatory forum

    US FDA and Telangana DCA bolster global pharma safety at second regulatory forum

    Nishant as Health Minister, Bihar is all set to witness a New Dawn of Healthcare

    Nishant as Health Minister, Bihar is all set to witness a New Dawn of Healthcare

    Six Women Develop Serious Complications After C-Section

    Six Women Develop Serious Complications After C-Section

    Cracks Down on Pharma Biological Firm in Bagru; Labeling Violations, Unapproved Claims and Quality Lapses Detected

    Cracks Down on Pharma Biological Firm in Bagru; Labeling Violations, Unapproved Claims and Quality Lapses Detected

    Indian Pharma Majors Plan to Invest in US

    Indian Pharma Majors Plan to Invest in US

    Emcure Pharmaceuticals Q4 net profit rises 24% to ₹243.74 cr

    Emcure Pharmaceuticals Q4 net profit rises 24% to ₹243.74 cr